Merck To Use Morphosys' HuCAL Gold Antibodies in Vaccine Research
August 05, 2011
Merck To Use Morphosys' HuCAL Gold Antibodies in Vaccine Research
The agreement grants Merck access to the company's HuCAL Gold antibody library for research purposes, as well as the option to upgrade to Morphosys's HuCAL Platinum library.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Big Pharma Exploring Targeted MS to Measure Key Transporter Proteins for Drug Development
August 12, 2011 / ProteoMonitor - BGI Aims to Expand Proteomics Services, Purchase 50-Plus New Mass Spectrometers
June 17, 2011 / ProteoMonitor - Morphosys Licenses Antibodies to Proteomika for Use in Companion Dxs
May 20, 2011 / ProteoMonitor - Movers & Shakers
May 13, 2011 / ProteoMonitor - Pfizer Integrating Immunoaffinity Mass Spec into Drug Development Pipeline
February 18, 2011 / ProteoMonitor